Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $425,000 a Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/24/2019 | 11:23am EDT

By Maria Armental

Novartis AG's gene therapy to treat a rare muscle-wasting disease that typically kills babies before age 2 was approved for sale in the U.S.

Zolgensma, a one-time injection to treat spinal muscular atrophy type 1 in children younger than 2, is the first gene therapy for pediatric patients.

SMA, as the hereditary disease is known for its acronym, is the leading cause of infant deaths.

There are four primary types of SMA based on age when symptoms first appear and highest milestone achieved. Many children with SMA type 1, a severe form and most common type, don't survive past the age of 2.

Novartis (NVS) said the annualized cost of Zolgensma will be $425,000 a year for five years.

Write to Maria Armental at maria.armental@wsj.com

Corrections & Amplifications

This article was corrected at 1:24 p.m. ET because an earlier version misspelled Zolgensma in the headline.

Corrections & Amplifications

This item was corrected at 6:23 p.m. ET. An earlier version misstated Novartis as Novaratis in the last paragraph.

This article is part of a news chaine.
Article 1 / 3
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
06/24NOVARTIS : provides update on phase 2b ENCORE-LF trial in NASH cirrhosis
PU
06/24GLENMARK PHARMACEUTICALS : Novartis Partner to Distribute COPD Products in Brazi..
DJ
06/24MEREO BIOPHARMA : Conversion of loan note and issue of equity
AQ
06/21European stocks pause after third week of gains
RE
06/21NOVARTIS : U.S. group says Novartis MS drug price out of line with benefit
RE
06/21GLOBAL MARKETS LIVE : Chevron Phillips, Nova, GSK, Slack…
06/20Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momen..
AQ
06/19Amphastar to Get $59.9 Million in Settlement With Momenta, Sandoz -- Update
DJ
06/19Amphastar to Get $59.9 Million in Settlement With Momenta, Sandoz
DJ
06/18NOVARTIS : New analysis of Novartis data confirms that Cosentyx demonstrates dur..
AQ
More news
Financials ($)
Sales 2019 46 781 M
EBIT 2019 12 304 M
Net income 2019 8 682 M
Debt 2019 15 312 M
Yield 2019 3,15%
P/E ratio 2019 22,91
P/E ratio 2020 20,89
EV / Sales 2019 5,32x
EV / Sales 2020 5,02x
Capitalization 234 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 91,0 $
Spread / Average Target -2,0%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS21.44%220 893
JOHNSON & JOHNSON10.10%348 981
PFIZER0.05%233 072
ROCHE HOLDING LTD.13.50%227 848
MERCK AND COMPANY11.91%206 641
ELI LILLY AND COMPANY-0.20%113 364